8-K: UNITY Biotechnology Announces Topline Results from ASPIRE Phase 2b Study in Diabetic Macular Edema

UNITY Biotechnology's UBX1325 shows promising vision gains in diabetic macular edema patients, comparable to aflibercept, in Phase 2b ASPIRE study.

Summary

• UNITY Biotechnology announced topline results from its ASPIRE Phase 2b study of UBX1325 in patients with diabetic macular edema (DME).
• The study compared UBX1325 to aflibercept in patients who had poor vision despite prior anti-VEGF treatment.
• UBX1325 treatment resulted in visual acuity gains of over 5 letters from baseline at weeks 24 and 36.
• UBX1325 was non-inferior to aflibercept at 9 out of 10 time points through 36 weeks, but did not meet statistical non-inferiority on the average of weeks 20 and 24 (achieving an 88% confidence interval compared to the pre-specified 90% threshold).
• The company plans to advance UBX1325 to late-stage studies against aflibercept in DME patients with inadequate response to anti-VEGF therapies.
• UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the promising vision gains shown by UBX1325, but tempered by the fact that it did not meet the primary endpoint for non-inferiority and the inherent risks in drug development.

Positives

• UBX1325 showed robust vision improvements in a difficult-to-treat patient population.
• UBX1325 generally outperformed aflibercept in patients who had moderate disease severity (baseline CST < 400 microns, representing ~60% of study patients).
• Patients who switched from aflibercept as their anti-VEGF treatment prior to study enrollment to UBX1325 had the most consistent and durable vision gains.
• UBX1325 continues to demonstrate a favorable safety and tolerability profile across multiple clinical studies to date.
• There have been no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis or vasculitis across multiple studies.

Negatives

• UBX1325 did not meet statistical non-inferiority to aflibercept on the primary analysis endpoint (average of weeks 20 and 24), achieving an 88% confidence interval compared to the pre-specified 90% threshold.
• Patients on UBX1325 had an increase in Central Subfield Thickness (CST) at weeks 16 and 20, which resulted in supplemental anti-VEGF treatments in patients with significant CST gain.

Risks

• The forward-looking statements involve substantial known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• Risks include delay or disruption in clinical trials, uncertainties inherent in the drug development process, and the company's ability to raise funding.

Future Outlook

UNITY anticipates advancing UBX1325 to late-stage studies against aflibercept in DME patients with inadequate response to anti-VEGF therapies and expects to report complete 36-week data results in the second quarter of 2025.

Management Comments

• Anirvan Ghosh, PhD, chief executive officer of UNITY, stated, 'We are excited that UBX1325 showed robust vision improvements in a difficult to treat patient population.'
• David S. Boyer, MD, stated, 'Achieving durable improvements in visual acuity via an entirely new mechanism of action as seen in this study is remarkable and would be invaluable for patients receiving sub-optimal response from current treatment options.'

Industry Context

The standard of care for DME treatment has been anti-VEGF-related agents for the last 20 years, but approximately half of patients have a sub-optimal response and discontinue treatment after 6 months, highlighting the need for alternative treatments like UBX1325.

Comparison to Industry Standards

• The study compares UBX1325 to aflibercept, a leading anti-VEGF product used as a standard of care for DME.
• The results suggest UBX1325 may provide greater vision gains than standard of care in patients with moderately aggressive disease, potentially offering an alternative for patients who don't respond well to anti-VEGF therapies.
• The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment.

Stakeholder Impact

• Positive impact on patients with DME who have not responded well to existing treatments, offering a potential new treatment option.
• Potential benefit to shareholders if UBX1325 progresses successfully through late-stage trials and receives regulatory approval.

Next Steps

• Advance UBX1325 to late-stage studies against aflibercept in DME patients with inadequate response to anti-VEGF therapies.
• Report complete 36-week data results in the second quarter of 2025.

Key Dates

Keywords

UBX1325, diabetic macular edema, DME, UNITY Biotechnology, aflibercept, ASPIRE Phase 2b study, visual acuity, anti-VEGF, retinal disease, senescent cells